Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Current Deferred Revenue for 7 consecutive years, with $12.5 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Current Deferred Revenue changed N/A year-over-year to $12.5 million, compared with a TTM value of $12.5 million through Mar 2025, changed N/A, and an annual FY2024 reading of $10.2 million, down 92.46% over the prior year.
  • Current Deferred Revenue was $12.5 million for Q1 2025 at Bicycle Therapeutics, up from $10.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $135.2 million in Q4 2023 and bottomed at $700000.0 in Q4 2022.
  • Average Current Deferred Revenue over 5 years is $34.4 million, with a median of $11.4 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue plummeted 99.02% in 2022, then skyrocketed 19213.43% in 2023.
  • Year by year, Current Deferred Revenue stood at $71.3 million in 2021, then tumbled by 99.02% to $700000.0 in 2022, then surged by 19213.43% to $135.2 million in 2023, then crashed by 92.46% to $10.2 million in 2024, then rose by 22.89% to $12.5 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BCYC at $12.5 million in Q1 2025, $10.2 million in Q4 2024, and $135.2 million in Q4 2023.